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Respiratory syncytial virus (RSV) is a common cause of severe lower respiratory tract diseases (bronchiolitis and pneumonia)
during infancy and early childhood. There is increasing evidence which indicates that severe pulmonary disease caused by RSV
infection in infancy is associated with recurrent wheezing and development of asthma later in childhood. However, the underlying
mechanisms linking RSV infection to persistent airway hyperresponsiveness and dysfunction are not fully deﬁned. To study these
processes in ways which are not available in humans, animal models have been established and have provided valuable insight into
the pathophysiology of RSV-induced disease. In this paper, we discuss experimental models of RSV infection in mice and highlight
anewinvestigativeapproachinwhichmiceareinitiallyinfectedasneonatesandthenreinfectedlaterinlife.Theﬁndingsshedlight
on the mechanisms underlying the association between early severe RSV infection and development of asthma later in childhood.
1.Introduction
Respiratory syncytial virus (RSV) is the leading cause of
viral lower respiratory tract infections (bronchiolitis and
pneumonia) during infancy and early childhood worldwide.
About 65% of children are infected with RSV within the ﬁrst
year of life, and almost all children are infected at least once
by2yearsofage.Notably,repeatedinfectioniscommonatall
ages; however, therapeutic options are limited and somewhat
ineﬀective.
Infants hospitalized with RSV-associated bronchiolitis
are at increased risk of recurrent wheezing and asthma
later in childhood [1]. However, in nonhospitalized patients,
the relationship is less clear [2], and indeed other viruses,
such as rhinovirus, have also shown predisposing attributes
[3]. The underlying mechanisms responsible for the inter-
actions between RSV infection and the development of
asthma are controversial. In general, animal disease models
provide opportunities to address issues such as underlying
mechanisms or potential therapeutic interventions that
are impossible to study in humans, especially when the
target population is the very young. Due to the variable
consequences of RSV-induced bronchiolitis, especially in
predisposed atopic compared to nonatopic infants, animal
models have been developed in an attempt to mimic the
clinical conditions. Here, we brieﬂy discuss mouse models of
RSV infection and a new investigative model with neonatally
infected mice that may elucidate the mechanisms underlying
the association between early severe RSV infection and
development of asthma later in childhood.
2. AnimalModels of RSVDisease
Many species have been used to develop animal mod-
els of human RSV disease including chimpanzees, calves,
cotton rats, guinea pigs, ferrets, hamsters, and mice [4].
Each of these models has both inherent advantages and
disadvantages. No single animal model duplicates all forms
of human RSV-related disease. When choosing a suitable
animal model, two factors must be considered. First, the
animal species should be susceptible to the virus, allowing
infection and replication. Second, the animal model should
mirror at least some aspects of human disease. The animal
models have contributed to understanding the pathogenesis
ofRSVinfectiontosomedegreeandhavebeenmostusefulin
testingdrugsthatinhibitvirusreplication.Mousemodelsare
themostwidelyusedsince(a)fromanimmunologicalstand-
point, mice are the best characterized animals and a large2 Pulmonary Medicine
pool of immunological reagents are available, (b) their body
size is small and the breeding period is short so experiments
can be performed in a cost- and time-eﬀective manner,
(c) a wide array of gene-manipulated mice (transgenic or
knockout mouse strains) have been generated which allow
direct assessment of the roles of single genes or related
proteins in development of disease, and (d) mouse models
have been widely used to investigate asthma, an advantage
to study the interaction between RSV infection and allergic
airway responses.
RSV is a negative-sense, single-stranded RNA virus of
the paramyxovirus subfamily pneumovirinae. The single
greatest disadvantage in using mouse models for studies of
the human RSV pathogen is that pneumoviruses are highly
restricted to their natural hosts. Human RSV is not a natural
rodent pathogen; therefore, a large inoculum of virus is
requiredtoachieveevenamodestdegreeofvirusreplication.
In the most permissive mouse strains, such as BALB/c,
challenge using an inoculum (1–10 million plaque-forming
units (pfu)) of human RSV wild-type (WT) strain A2 or the
WT long strain is required to achieve productive infection.
A high dose (107–108 pfu) may cause severe alveolitis with
pneumonia, whereas a lower dose (105–106 pfu) mainly
causes bronchiolitis with no alveolitis or pneumonia. For
these reasons, some groups have used pneumonia virus of
mice (PVM), the mouse equivalent strain of human RSV.
Because PVM is a natural rodent pathogen, far fewer virions
are required to induce infection. PVM replicates to high
titers in the mouse lung but can cause severe disease with
signiﬁcant mortality in immunocompetent hosts, which is
rarely seen in humans. As little as 2 pfu elicits a respiratory
tract infection, ∼30 pfu provokes a productive infection with
severe bronchiolitis, and 300 pfu results in rapid death [5].
However, antiviral therapies speciﬁc to human viruses (e.g.,
neutralizing antibodies) cannot be tested in these models
using nonhuman viruses.
Most of the studies with mouse models were initiated
by intranasal inoculation of human RSV. Viral replication,
airway inﬂammation, innate and adaptive immunity, and
airway responsiveness are measured at diﬀerent time points
after RSV infection. Virus replication in the lung usually
peaks 3-4 days after infection, and clearance is generally
achieved by 2-3 weeks after inoculation. However, evidence
for RSV RNA which persisted in lung homogenates for 100
days or more has recently been demonstrated [6, 7]. The
signiﬁcance of such virus persistence is not clear, and it is not
known whether the persisting virus can cause any form of
chronic airway disease. In general, RSV infection can induce
secretion of cytokines such as IFN-γ, IL-4, IL-5, IL-10, IL-12,
IL-13,andchemokinessuchasCCL2,CCL3,CCL5,CXCL10,
and KC [8]. RSV infection also induces the generation of
lipid inﬂammatory mediators, such as cysteinyl leukotrienes
[9, 10]. Many immune and inﬂammatory cells are involved
in acute RSV infection, including neutrophils, dendritic cells
(DCs), macrophages, natural killer (NK) cells, natural killer
T(NKT)cells,Tcells,andeosinophils.Ithasbeenrecognized
that the host immune responses to RSV are responsible
for a substantial portion of RSV-induced pathophysiological
changes [11–13]. In the context of this discussion, RSV
infection induces airway hyperresponsiveness (AHR) to
inhaled methacholine (MCh) [14, 15]. Schwarze et al.
showed that acute RSV infection in mice results in AHR
and neutrophilic and eosinophilic inﬂammation [14]. This
response is associated with the predominant production of
Th1-type cytokines from peribronchial lymph node cells in
vitro. The development of AHR to inhaled MCh peaked
on day 7 after RSV infection [16], and 14–21 days after
RSV infection, AHR resolved to baseline levels. Epithelial
cell damage, inﬂammation, and neural pathways have been
shown to be involved in RSV-induced AHR in mice [17, 18].
Theextentanddurationoflunghistopathologymayvary
depending on the particular model selected. A number of
factors must be taken into consideration when interpreting
data from these diﬀerent models: (a) the dose of virus
inoculum, (b) the strain and purity of the virus: the
virus preparation should be puriﬁed and inoculated free
of culture-derived factors (cytokines, chemokines, etc.) that
could potentially modify the host’s response to the virus.
(c) The route of inoculation: in most studies, RSV is
given intranasally, but in some animal models RSV is given
intratracheally.Intratrachealinoculationmayrequirealower
dose of RSV to achieve similar lung histopathology. (d) The
strain of mouse used: BALB/c mice are the most commonly
used strain because they appear to be the most permissive
for human RSV. However, BALB/c mice tend to be more
proﬁcient in producing Th2 responses than other strains
such as C57BL/6 mice [19]. (e) The last factor is the age of
mice at the point of viral inoculation.
3 .M o us eM od el so fA s t h m a
Asthma is a complex syndrome of unknown etiology. Mouse
models are the most commonly used animal model to study
the pathogenesis of asthma. Experimental asthma is usually
induced by initial systemic sensitization to allergen together
with alum as an adjuvant followed by airway challenge with
aerosolized allergen for 1–9 days in acute models and for 5–9
weeks in chronic models. In these models, diﬀerent strains of
mice(withdiﬀerentsusceptibilities)canbeused.Inaddition,
the mode of sensitization (with or without adjuvant), the
route of sensitization (systemic or local airway sensitization),
and the frequency and duration of airway allergen challenge
can be varied, leading to identiﬁcation of various pathways
and mechanisms that perhaps reﬂect the heterogeneity of
human asthma [20, 21].
To investigate the interaction of RSV infection and
asthma, these experimental asthma models are combined
with RSV infection, either prior to or following allergen
challenge, uncovering mechanisms whereby viral infections
may contribute to the pathophysiology of asthma.
4. Effects of Prior Airway Allergen Exposure on
RSV-Induced AirwayResponses
Following RSV infection, most individuals develop mild
symptoms, which are usually restricted to the upper airways
[22]. This is in contrast to subjects with underlying diseases
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a deﬁcient antiviral response and spread to the lower airways
where they mediate tissue damage and inﬂammation. This
can result in exaggerated constrictive airway responses
to both allergen and nonspeciﬁc stimuli [23]. Indeed, a
viral infection is the most common cause of an asthma
exacerbation [24].
In earlier studies, when BALB/c mice were previously
exposed to OVA via the airways followed by RSV infection,
the degree of AHR was signiﬁcantly increased and was
associated with an increased proportion of Th2 (IL-4, IL-5)
cytokine-producing T lymphocytes [25]. This response
was also associated with the increased accumulation of
eosinophils, neutrophils, and CD8+ T cells in the lungs.
These results suggested that airway allergen exposure prior
to RSV infection may predispose sensitized hosts to a greater
degree of RSV-induced AHR and airway inﬂammation. Sim-
ilarly, when using a diﬀerent trigger, ultraﬁne carbon black
(CB) particles, Lambert et al. demonstrated a synergistic
eﬀect of ultraﬁne CB particles with RSV infection on the
development of airway inﬂammation and AHR in BALB/c
mice [26]. These data indicate that prior exposure to allergen
in a sensitized host can lead to enhanced Th2-dominant
immune responses against RSV. Among the Th2 cytokines
released following RSV infection in “allergic” animals, IL-
4, IL-5, and IL-13 are involved in development of airway
eosinophilia and AHR [25, 27, 28].
5. Effects of InitialRSV Infection on
SubsequentAirwayAllergic Responses
It appears that RSV infection, particularly in children under
1 year old with severe bronchiolitis requiring hospitalization,
has a strong linkage to development of allergic asthma [29–
31]. An ongoing debate that remains unresolved is whether
RSVcaninduceasthmaandwhethertheresponseisdiﬀerent
in atopic compared to nonatopic infants. Certainly, the
presence of IgE antibodies to RSV has been linked to more
severe disease [32]. The development of clinical strategies
is in many ways tied to our thinking. For example, the
prevention of RSV lower respiratory tract infection, with the
use of anti-RSV monoclonal antibody therapy, has shown
some beneﬁt in “preventing” asthma in some but not all
studies [33]. If RSV is truly an initiator of asthma, then
RSVpreventiveinterventionscouldreduceor,ataminimum,
delay the onset of asthma. Such interventions might be most
eﬀective among those genetically predisposed to more severe
RSV infection and asthma. A recent study demonstrated
that RSV prophylaxis in nonatopic children decreases the
relative risk of recurrent wheezing by up to 80% but has little
to no eﬀect in infants with an atopic family history [34].
Although remaining to be conﬁrmed, the ﬁndings suggest
that RSV may predispose to recurrent wheezing in an atopy-
independent manner. Two recent clinical studies addressing
causation between infant RSV infection and asthma came
to diﬀerent conclusions. Wu and colleagues found that 4-
month-old infants at the winter virus peak, which means
that they likely were exposed to an entire RSV season at
an age when they were most susceptible to develop severe
RSV-associateddisease,hadanincreasedriskofbronchiolitis
in infancy and then of asthma during childhood [35]. By
contrast, Thomsen and colleagues, using a large dataset of
8,280 twin pairs in Denmark, found that the association
between RSV and asthma was essentially due to shared
genetic predisposition [36]. However, both studies suﬀered
from inadequate phenotypic deﬁnition of RSV infection and
of asthma and failed to shed further light on the continuing
debate.
Despite the many limitations of animal studies, con-
trolled experiments can be carried out to directly determine
the interplay between RSV and allergic sensitization and
the development of an asthma-like phenotype. When RSV
is administered after allergen exposure, this combination
results in the development of a greater degree of AHR as
described above [25, 26]. Barends et al. demonstrated that
RSV infection during the provocation phase to allergen
enhanced pulmonary expression of Th2 cytokines, lung
pathologic lesions, and AHR but not Th1 responses [37].
The same group further demonstrated that the timing of
RSV infection was critical for such RSV-enhanced allergic
responses. When the immune system was Th2-primed by
allergen (i.e., OVA), inoculation with RSV enhanced the
allergic responses [38]. This is consistent with substantial
clinical and epidemiologic evidence that RSV infection
triggers exacerbations of asthma. Strong links between viral
infection and acute worsening of asthma have been shown
in approximately 80% of cases in children [39] and 70% in
adults [40].
However, when RSV infection precedes airway allergen
exposure, the experimental results are inconsistent. In an
approach where OVA aerosolization began 10 days after
RSV infection in BALB/c mice, Schwarze et al. demon-
strated that mice sensitized to OVA via the airways after
RSV infection developed increased AHR, and pulmonary
eosinophilic and neutrophilic inﬂammation, associated with
the predominant production of Th2-type cytokines [14].
Furthermore, treatment with anti-IL-5 antibody abolished
AHR and eosinophilic but not neutrophilic inﬂammation
in both RSV-infected and RSV-infected followed by OVA
exposure groups. Freihorst et al. [41] showed signiﬁcantly
higherOVA-speciﬁcIgGinRSV-infected,allergenchallenged
BALB/c mice than the uninfected, OVA-challenged controls.
Similar results have been reported in guinea pigs and
calves [42, 43]. In contrast, Peebles et al. showed that RSV
infection prior to allergic sensitization protected against the
development of allergen-induced AHR and allergic airway
inﬂammation [44]. Liu and Kimura observed similar results
when using Japanese cedar pollen (JCP) as the allergen
[45]. These discrepancies may reﬂect the complexity of RSV
infection, diﬀerences among virus strains, and the approach
to infection, all which can lead to diﬀerences in the extent of
Th1 and Th2 responses. The genetic background of the mice,
age at infection or allergen exposure, prior exposure to RSV,
or allergen or microbial infections may all contribute to the
diﬀerences in Th1/Th2 balance. Together, the data suggest
thattheairwayresponsetoallergenmaydependonthehost’s
immune setting induced by the prior RSV infection.
To mimic the human clinical situation more closely,
some groups have employed an approach where BALB/c4 Pulmonary Medicine
mice were neonatally infected with PVM followed by OVA
sensitization and challenge, but after the airways were fully
recovered from virus infection [46]. In this model, they
found that early-life virus infection or allergen sensiti-
zation and challenge were independent variables capable
of contributing to development of childhood asthma and
that these interactions between early-life viral infection and
allergen sensitization/challenge were essential for the full
development of the characteristic features of childhood
asthma, including eosinophilic inﬂammation and a Th2-
biased immune response. This may explain how PVM, on its
own or in conjunction with allergic sensitization, triggers an
asthma-like phenotype.
In addition to OVA, house dust mite (HDM), a common
allergen in asthma, has been used to induce experimental
models of asthma in mice. Studies examining the eﬀects of
RSV infection in HDM-exposed animals are less common.
In one, RSV infection 3 days before HDM sensitization aug-
mentedDerf-speciﬁcantibodyproductionandincreasedthe
number of blood eosinophils [47]. As in OVA models, RSV
infection exacerbated pulmonary allergic responses to sub-
sequent HDM exposure [48]. Recurrent RSV infections after
HDM sensitization augmented synthesis of Th2 cytokines,
total serum IgE, and MIP-1α, which resulted in persistent
airway inﬂammation and airway hyperresponsiveness [49,
50].
6. Characterization of the Consequences of
RSV Reinfection
Compared with other respiratory viruses, RSV infections
appear more frequent and often more severe early in life.
RSV has been implicated in mortality in the elderly [51].
The peak for hospitalization with RSV is at 2 months of age
[22]. Infants at this young age have narrower airways and are
more susceptible to obstruction, a prominent feature of RSV
disease.Immuneresponsesingeneralarelowerinmagnitude
and potentially less eﬀective in young infants than in older
children or adults. In addition, there is a Th2 bias in immune
response during the neonatal period [52, 53]. Compared
to controls, a higher frequency of IL-4 producing T-cells
responding to RSV and cat antigens were found in children
who were hospitalized with RSV bronchiolitis in infancy
[54].RSVinfectionduringtheﬁrst3monthsoflifeinducesa
Th2-biased response compared to infection in older infants
[55]. As infancy is a time of rapid lung maturation, severe
airway inﬂammation may alter lung structure permanently
and result in airway remodeling. Taken together, all of these
features point to a period of increased susceptibility in early
infancy. Interestingly, this also holds true for other viruses,
suchashumanparainﬂuenzavirus(HPIV)orinﬂuenzavirus
and thus may be more related to host age rather than any
particular feature of the virus [55]. However, since RSV
infects infants very early in life, the overall impact appears
greater for RSV. This age eﬀect appears to be true for allergic
sensitization as well. In this regard, allergen sensitization at
early age establishes long-lasting memory T cell responses
whichcanbeactivatedafterairwayallergenchallengecausing
AHR months after initial sensitization in mice [56].
An important aspect of RSV infection is that reinfection
is common in children and is associated with wheezing
and asthma after an episode of bronchiolitis [22]. Infection
in a Th2-biased environment has the potential to aﬀect
the overall quality and nature of both primary and recall
responses. Once infants become sensitized to RSV and a
long-lasting type 2 immune response is established in the
airways,theymaygoontodeveloprecurrentairwaydysfunc-
tion (wheezing and perhaps asthma) on re-exposure to RSV.
Reinfection with RSV has been examined in mice. Culley
et al. found that primary infection of neonatal mice (during
the ﬁrst week of life) with RSV was associated with reduced
and delayed IFN-γ responses [57]. Upon reinfection, these
m i c ed e v e l o p e dm o r es e v e r ew e i g h tl o s sw i t haT h 2 - b i a s e d
lymphocyte response and airway eosinophilia compared
with mice initially infected with RSV at an older age. We
adopted a similar approach to examine the consequences of
reinfection with RSV and to determine how the responses
diﬀer if initial infection was in neonates or weanling
animals, in particularexamining the consequenceson airway
responsiveness [16]. We showed that both age groups can
develop signiﬁcant AHR after primary RSV infection either
at 1 or 3 weeks of age. When re-infected with RSV 5 weeks
later, the two age groups developed very diﬀerent airway
responses. Initial RSV infection at 3 weeks of age elicited
a protective airway response upon reinfection characterized
by an increased airway inﬂammatory response consisting
primarily of lymphocytes, but without development of
AHR, eosinophilia, or mucus hyperproduction. In contrast,
initial neonatal infection failed to protect the airways on
reinfection and resulted in enhanced AHR, increased IL-
13 production associated with mucus hyperproduction and
airway eosinophilia (Figure 1)[ 16]. Moreover, IL-13 was
shown to be critical to the development of the asthma-
like phenotype after reinfection of mice initially infected as
newborns.
The underlying mechanisms responsible for these sig-
niﬁcant age diﬀerences are not entirely deﬁned. In infants,
an association between severity of RSV bronchiolitis and
deﬁcient IFN-γ production has been demonstrated [58–61].
Infants hospitalized for severe lower respiratory tract illness
due to RSV infection had lower IFN-γ production from
blood mononuclear cells compared to those with milder
illnesses [58, 59]. Moreover, the levels of IFN-γ measured in
nasopharyngeal aspirates were lower in infants hospitalized
for severe RSV bronchiolitis compared to those exhibiting
milder disease. These clinical studies suggested that IFN-γ
plays an important role in determining the outcome of RSV-
mediated disease. Similarly, in animal models, we and others
found that neonates demonstrated lower IFN-γ responses
to initial RSV infection compared with weanling or adult
mice [16, 57] .T h ep r o t e c t i v er o l eo fI F N - γ was conﬁrmed
in the RSV reinfection model using IFN-γ-deﬁcient mice
[62]. Here, when initial infection and reinfection were
carried out in adult mice, IFN-γ-deﬁcient mice developed
signiﬁcantly greater AHR, airway eosinophilia, and mucus
hyperproduction following reinfection compared to the WT
mice, regardless of the absence of signiﬁcant diﬀerences in
the response to initial infection. Provision of IFN-γ duringPulmonary Medicine 5
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Figure 1: Age-related diﬀerences in airway responses. (a) Primary infection, (b) secondary infection.
primary neonatal infection prevented the development of
enhanced AHR and lung histopathology upon reinfection
with RSV. These results indicated a critical role for IFN-γ
during the initial infection stage that dictated the subsequent
outcomes of reinfection with RSV. This may also be true
in humans so that provision of IFN-γ in infancy may
interfere with the development of altered airway responses
on reinfection at a later age.
Speciﬁc IgE antibodies against viral pathogens have
been identiﬁed in clinical studies following diﬀerent viral
infections, including RSV [32]. In most cases, development
of virus-speciﬁc IgE has been associated with a more severe
disease outcome [63, 64]. In the mouse model, primary
RSV infection can also lead to the production of RSV-
speciﬁc IgE, which may contribute to the development of
exaggerated airway responses upon reinfection. Thus, there
is a certain parallelism between RSV-mediated wheezing
and allergen-triggered asthma. In the mouse reinfection
model, we demonstrated that RSV-speciﬁc IgE enhances
the development of Th2-biased airway responsiveness on
reinfection of mice initially infected as neonates [65]. How
RSV infection leads to an increase in RSV-speciﬁc IgE
production, a hallmark of Th2 responses, and enhancement
of disease is not clear. Recent studies using mouse Sendai
virus (SeV) infection sheds new light on the potential
mechanisms [66]. These studies showed that infection with
mouse SeV led to increased expression of the high-aﬃnity
IgE receptor (FcεRI) on lung DCs, and this was type I
interferonreceptordependent.CrosslinkingofFcεRIonDCs
resulted in CCL28 production, subsequent recruitment of
IL-13-producing CD4+ T cells and development of mucus
metaplasia. Thus, the development of virus-speciﬁc IgE may
play a critical role in reinfection-induced allergic airway
inﬂammation and AHR.6 Pulmonary Medicine
7. Conclusions
There is now suﬃcient evidence supporting the notion that
severe infantile RSV infection is associated with recurrent
wheezing and asthma later in childhood. However, the
underlying mechanisms are not fully deﬁned nor are the
ﬁndings always consistent, perhaps suggesting genetic and
environmental risk factors playing a role in dictating ﬁnal
outcomes. In early life, the tendency towards Th2-biased
responses is likely an important variable, especially in hosts
that are atopic or predisposed to becoming atopic. RSV
infection in neonates may bias both the systemic immune
response and the response in the lung. This in turn could
lead to the development of asthma-like symptoms when
re-exposed to RSV. Further, this Th2-biased setting seen
with RSV reinfection and the development of IgE-speciﬁc
antibodies may induce some cross-sensitization or lower the
threshold to allergen-induced responses. This combination
may manifest as increased asthma susceptibility. Studies in
the mouse, although not complete surrogates of human dis-
ease, have provided valuable information in understanding
the potential links between RSV infection and asthma.
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